RAPT Therapeutics, Inc. (RAPT) Gains from Sales and Divestitures (2021 - 2024)
RAPT Therapeutics (RAPT) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $13500.0 as the latest value for Q3 2024.
- Quarterly Gains from Sales and Divestitures changed 0.0% to $13500.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $13500.0 through Sep 2024, changed 0.0% year-over-year, with the annual reading at $13500.0 for FY2023, 0.0% changed from the prior year.
- Gains from Sales and Divestitures hit $13500.0 in Q3 2024 for RAPT Therapeutics, roughly flat from $13500.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $14125.0 in Q1 2021 to a low of $13500.0 in Q1 2022.
- Historically, Gains from Sales and Divestitures has averaged $13666.7 across 4 years, with a median of $13500.0 in 2022.
- Biggest five-year swings in Gains from Sales and Divestitures: fell 4.42% in 2022 and later changed 0.0% in 2023.
- Year by year, Gains from Sales and Divestitures stood at $14125.0 in 2021, then decreased by 4.42% to $13500.0 in 2022, then changed by 0.0% to $13500.0 in 2023, then changed by 0.0% to $13500.0 in 2024.
- Business Quant data shows Gains from Sales and Divestitures for RAPT at $13500.0 in Q3 2024, $13500.0 in Q2 2024, and $13500.0 in Q1 2024.